GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Fezolinetant tablets (Veozah)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Fezolinetant tablets (Veozah) - selected U.S. label sections

Product / population
VEOZAH oral tablets for the labeled menopausal vasomotor-symptom indication.
Renal method
eGFR in mL/min/1.73 m2
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Official

Fezolinetant tablets (Veozah) - selected U.S. label sections

Open original reference

U.S. product labeling / DailyMed · VEOZAH oral tablets for the labeled menopausal vasomotor-symptom indication.

Renal method: eGFR in mL/min/1.73 m2
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal restrictions

Mild impairment (eGFR 60 to below 90) and moderate impairment (30 to below 60) do not require adjustment. Severe impairment (15 to below 30) and end-stage disease (below 15) are contraindications.

RDM32-fezolinetant-veozah-1 · Source locator: 4; 8.6

Additional mandatory safety review

The boxed warning concerns hepatotoxicity. Obtain hepatic laboratory tests before initiation, monthly for the first 3 months, and at months 6 and 9. Cirrhosis and concomitant CYP1A2 inhibitors are also contraindications. A renal eligibility finding alone does not establish treatment eligibility.

RDM32-fezolinetant-veozah-2 · Source locator: Boxed warning; 2.1; 4; 5.1

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cae9f798-24f9-4580-a4fc-e6c710cbda3c
Retrieved
2026-09-05
DailyMed Set ID
cae9f798-24f9-4580-a4fc-e6c710cbda3c
Renal-function method
eGFR in mL/min/1.73 m2
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
fdf0fba4070963a240c8484af82f3d09d4691821ed11f37d3672100ce617d672

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=fezolinetant-veozah&s1=RDM32-label-fezolinetant-veozah&h1=38672f57b62ba672eebad5e549e3eb2a578ef7eb1a8223750a83dc4f1be97ad4